Second‐line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study
2018 · British Journal of Haematology · 94 citations
https://doi.org/10.1111/bjh.15149
X
Xiaolei Zhou
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
166
Papers
5.8K
Citations
31
h-index
55
i10-index
Xiaolei Zhou is an academic researcher from Guangxi Medicinal Botanical Garden. The author has contributed to research in topics: Lymphoma Diagnosis and Treatment & Viral-associated cancers and disorders & interferon and immune responses. The author has an h-index of 31, co-authored 142 publications.
ORCID: 0000-0002-7992-637XPapers by this author
worksHealth-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment
2011 · British Journal of Cancer · 58 citations
https://doi.org/10.1038/bjc.2011.409
Patient-Reported Outcomes in Patients With <i>PIK3CA</i>-Mutated Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer From SOLAR-1
2021 · Journal of Clinical Oncology · 34 citations
https://doi.org/10.1200/jco.20.01139
Assessing Methotrexate Adherence in Rheumatoid Arthritis: A Cross-Sectional Survey
2015 · Rheumatology and Therapy · 27 citations
https://doi.org/10.1007/s40744-015-0011-1
Protective effects of bone marrow mesenchymal stem cell-derived exosomes loaded cerium dioxide nanoparticle against deoxynivalenol-induced liver damage
2025 · Journal of Nanobiotechnology · 7 citations
https://doi.org/10.1186/s12951-025-03316-y
A fibrin gel-loaded Gouqi-derived nanovesicle (GqDNV) repairs the heart after myocardial infarction by inhibiting p38 MAPK/NF-κB p65 pathway
2025 · Journal of Nanobiotechnology · 5 citations
https://doi.org/10.1186/s12951-025-03615-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat